Exelixis (EXEL) Total Liabilities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Total Liabilities of $657.8 million in Q2 2026, down 3.7% quarter-over-quarter from $683.1 million in Q1 2026, and down 6.85% on a YoY basis from $706.2 million in Q2 2025.
Exelixis (EXEL) Total Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Liabilities history runs 17 years deep, the most recent figure standing at $657.8 million for Q2 2026.
- In Q2 2026, Total Liabilities fell 6.85% year-over-year to $657.8 million; the TTM figure through Apr 2026 stood at $657.8 million (down 6.85% YoY), while the FY2026 annual figure was $683.1 million, down 2.9% from the prior year.
- Total Liabilities was $657.8 million for Q2 2026 at Exelixis, down from $683.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $706.2 million in Q2 2025 to a low of $360.3 million in Q2 2022.
- Historically, Total Liabilities has averaged $616.8 million across 5 years, with a median of $653.4 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Total Liabilities surged 63.27% in 2023, then declined 6.85% in 2026.
- A 5-year view of Total Liabilities shows it stood at $583.1 million in 2022, then rose by 16.36% to $678.4 million in 2023, then rose by 0.95% to $684.9 million in 2024, then retreated by 3.21% to $662.8 million in 2025, then decreased by 0.75% to $657.8 million in 2026.
- The last three Total Liabilities figures came in at $657.8 million (Q2 2026), $683.1 million (Q1 2026), and $662.8 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 19.51 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 10.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 137.56 Mn |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 657.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 657.85 Mn |
| Jan 2, 2026 | 683.10 Mn |
| Oct 3, 2025 | 662.85 Mn |
| Jul 4, 2025 | 644.55 Mn |
| Apr 4, 2025 | 706.22 Mn |
| Jan 3, 2025 | 703.49 Mn |
| Sep 27, 2024 | 684.86 Mn |
| Jun 28, 2024 | 653.39 Mn |
| Mar 29, 2024 | 675.74 Mn |
| Dec 29, 2023 | 678.45 Mn |
| Sep 29, 2023 | 629.29 Mn |
| Jun 30, 2023 | 614.53 Mn |
| Mar 31, 2023 | 588.22 Mn |
| Dec 30, 2022 | 583.06 Mn |
| Sep 30, 2022 | 469.97 Mn |
| Jul 1, 2022 | 490.14 Mn |
| Apr 1, 2022 | 360.27 Mn |
| Dec 31, 2021 | 405.62 Mn |
| Oct 1, 2021 | 335.29 Mn |
| Jul 2, 2021 | 324.19 Mn |